MRNA vs ARGX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARGX Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to argenx SE American Depositary Shares (ARGX) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ARGX at 27.8x Forward P/E and 31.9% operating margin (+52.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against ARGX sits in UNCLASSIFIED (33rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | ARGX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $59.3B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 32.6x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 27.8x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +52.1% | Higher Growth | ARGX |
| Operating Margin (TTM) Profitability | -80.8% | 31.9% | Higher Margin | ARGX |
| Net Profit Margin Profitability | -110.5% | 31.7% | Higher Margin | ARGX |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 23.6% | Higher ROE | ARGX |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 64% ($662โ$1,073) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.56ฮฒ ยท 31% Vol | Lower Realized Risk | ARGX |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 49.6 / 100 (HOLD) | Higher Composite | ARGX |